Angiopoietin‐2, its soluble receptor Tie‐2, and metabolic syndrome components in a population‐based sample. Issue 10 (7th September 2016)

• Record Type: Journal Article
• Authors: Lorbeer, Roberto; Baumeister, Sebastian E.; Dörr, Marcus; Nauck, Matthias; Grotevendt, Anne; Schlesinger, Sabrina; Teumer, Alexander; Völzke, Henry; Grabe, Hans‐Jörgen; Wallaschofski, Henri; Vasan, Ramachandran S.; Lieb, Wolfgang
• Is Part Of: Obesity. Volume 24:Issue 10(2016)
• Page Start: 2038
• Page End: 2041
• Publication Date: 2016-09-07
• Subjects: Obesity -- Periodicals; 616.398005
• DOI: 10.1002/oby.21632
• Languages: English
• ISSNs: 1930-7381

Abstract

Abstract : Objective: Since angiopoietin‐2 (Ang‐2) levels strongly correlate with cardiovascular mortality and subclinical cardiovascular disease, it was hypothesized that levels of Ang‐2 and its soluble receptor (sTie‐2) were associated with the metabolic syndrome (MetS) and individual MetS components. Methods: Within the population‐based Study of Health in Pomerania, two sets of analyses were performed. First, Ang‐2 and sTie‐2 were related to the prevalence of MetS and its components cross‐sectionally ( n = 3, 205). Second, the association between baseline Ang‐2 and sTie‐2 and incident MetS or longitudinal changes in its components in 1, 295 individuals was investigated. Results: High Ang‐2 levels (90th percentile), compared with low Ang‐2 levels (10th percentile), were positively associated with MetS (OR: 1.78) and with the following MetS criteria: increased triglycerides, lower HDL cholesterol, and higher non‐fasting glucose. Furthermore, high sTie‐2 levels (90th percentile), compared with low levels (10th percentile), were positively related to MetS (OR: 1.58) and most of its components. However, Ang‐2 and sTie‐2 levels were not associated with incident MetS or longitudinal change in components of MetS. Conclusions: Ang‐2 and sTie‐2 levels were cross‐sectionally associated with MetS and several of its components. However, Ang‐2 and sTie‐2 levels were not associated with incident MetS or changes in individual MetS components during follow‐up.